Drugs / B/F/TAF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04143594 Comparator | Nov 2019 → Oct 2021 | HIV infectious disease | Gilead Sciences | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B/F/TAF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04143594 ↗ |
| Route | Oral | “(B/F/TAF) (50/200/25 mg) FDC tablets once daily orally from Day 1” NCT04143594 ↗ |